Acoramidis Shows Promise in Reversing Cardiac Disease Progression in ATTR-CM Trial

New clinical data demonstrates that Acoramidis significantly increases days alive and free from hospitalization while reversing structural disease progression in patients with transthyretin amyloid cardiomyopathy.

30 Aug, 14:00 — 30 Aug, 14:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual1d ago

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM - Taiwan News

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Taiwan News

Read full article →

Acoramidis Shows Promise in Reversing Cardiac Disease Progression in ATTR-CM Trial

Sources

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM - Taiwan News

Related Stories

South Korean Intelligence Detects Early Signs of Renewed US-North Korea Dialogue

Death Toll Surpasses 1,000 After Catastrophic Himalayan Floods

Nicolás Maduro Releases Photos From U.S. Detention Showing Significant Weight Loss

Nepal-China flood death toll exceeds 1,000 as Nepal PM demands climate action